Besides, the degree of immune activation of high B cell/DC1 infiltration tumor tissues was equivalent to that of normal tissues, and this part of the tumor tissues tended to be closer to normal tissues (Figure 6), which further demonstrated that the high B cell/DC1 infiltration group was immune activated and more suitable for ICB therapy. The gene discussed is ZDHHC4; the disease is neoplasm.